Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALLR
Upturn stock ratingUpturn stock rating

Allarity Therapeutics Inc (ALLR)

Upturn stock ratingUpturn stock rating
$1.5
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ALLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9 Target price
52w Low $0.61
Current$1.5
52w High $5.36

Analysis of Past Performance

Type Stock
Historic Profit -51.93%
Avg. Invested days 14
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 21.93M USD
Price to earnings Ratio 0.26
1Y Target Price 9
Price to earnings Ratio 0.26
1Y Target Price 9
Volume (30-day avg) 1
Beta 0.07
52 Weeks Range 0.61 - 5.36
Updated Date 08/29/2025
52 Weeks Range 0.61 - 5.36
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 5.75

Earnings Date

Report Date 2025-08-15
When -
Estimate -0.21
Actual -0.15

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -41.03%
Return on Equity (TTM) -150.58%

Valuation

Trailing PE 0.26
Forward PE -
Enterprise Value 5503454
Price to Sales(TTM) -
Enterprise Value 5503454
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.08
Shares Outstanding 14619600
Shares Floating 14619636
Shares Outstanding 14619600
Shares Floating 14619636
Percent Insiders 2.71
Percent Institutions 1.95

ai summary icon Upturn AI SWOT

Allarity Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Allarity Therapeutics, Inc. (formerly Oncology Venture) is a precision medicine company founded in 2006. It focuses on developing oncology drugs based on its proprietary DRPu00ae biomarker technology to predict patient response to specific therapies. It has undergone rebranding and strategic shifts over time.

business area logo Core Business Areas

  • Drug Development: Develops oncology drugs based on the DRPu00ae biomarker platform, aiming for personalized cancer treatment.
  • DRPu00ae Biomarker Platform: Provides a proprietary diagnostic tool to identify patients most likely to respond to specific cancer therapies.

leadership logo Leadership and Structure

The leadership team typically consists of a CEO, CFO, CSO, and a board of directors. Organizational structure is a typical biopharmaceutical company, with research and development, clinical operations, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Stenoparib: A PARP inhibitor in clinical development for ovarian cancer. Market share data is not publicly available as it is not yet approved. Competitors include GSK (Zejula), AstraZeneca/Merck (Lynparza), and Clovis Oncology (Rubraca).
  • Dovitinib: A multi-targeted receptor tyrosine kinase (RTK) inhibitor being developed for renal cell carcinoma. Market share data is not yet available due to its development stage. Competitors include approved tyrosine kinase inhibitors like Sutent and Inlyta.

Market Dynamics

industry overview logo Industry Overview

The oncology drug market is large and growing, driven by increasing cancer incidence and advances in treatment. Precision medicine is a key trend, with emphasis on targeted therapies and biomarker-driven patient selection.

Positioning

Allarity Therapeutics aims to differentiate itself with its DRPu00ae biomarker technology, which seeks to improve patient outcomes by identifying likely responders. However, it competes with larger, established pharmaceutical companies.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars. Allarity's position within this TAM is dependent on successful clinical trials and regulatory approvals of its pipeline assets. DRP's potential to personalize treatments impacts its TAM.

Upturn SWOT Analysis

Strengths

  • Proprietary DRPu00ae biomarker technology
  • Focus on personalized cancer treatment
  • Pipeline of drug candidates in clinical development

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trial outcomes
  • Relatively small company size compared to competitors

Opportunities

  • Potential to partner with larger pharmaceutical companies
  • Expansion of DRPu00ae technology to other cancer types
  • Regulatory approval of Stenoparib or Dovitinib

Threats

  • Clinical trial failures
  • Competition from established oncology drugs
  • Regulatory hurdles
  • Difficulty in raising capital

Competitors and Market Share

competitor logo Key Competitors

  • GSK (GSK)
  • AstraZeneca (AZN)
  • Merck (MRK)
  • Clovis Oncology (Not Public)

Competitive Landscape

Allarity faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Allarity's success hinges on its proprietary biomarker technology.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been minimal, characterized by clinical development efforts rather than revenue growth.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst projections are speculative.

Recent Initiatives: Recent initiatives include advancing Stenoparib and Dovitinib through clinical trials, and continued biomarker development.

Summary

Allarity Therapeutics is a small biotechnology company with promising biomarker technology. However, its limited resources and dependence on clinical trial success pose significant risks. The company needs to either get a product approved or seek an acquisition to succeed. It should focus on its biomarker technology to help it gain a competitive edge against the larger players in the market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Data may be based on estimates and subject to change. Market share data is based on available information and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Allarity Therapeutics Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2021-12-21
Founder, CEO & Director Mr. Thomas H. Jensen
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.